Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports

Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant tre...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of international medical research Ročník 44; číslo 1_suppl; s. 67 - 71
Hlavní autori: De Simone, Clara, Perino, Francesca, Caldarola, Giacomo, D’Agostino, Magda, Peris, Ketty
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London, England SAGE Publications 01.09.2016
Predmet:
Immuno-Mediated Diseases And Comorbities
Antitumour necrosis factor-α agents
psoriatic arthritis
comorbidities
etanercept
psoriasis
ISSN:0300-0605, 1473-2300, 1473-2300
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0300-0605
1473-2300
1473-2300
DOI:10.1177/0300060515593250